The market for orphan drug products continues to expand and developing new treatments for rare diseases is becoming an increasingly important growth area for many pharmaceutical companies. This interest in rare and orphan diseases is linked not only to the incentives offered by the different regulatory authorities but also to the recent development of advanced therapies.
The interactive course will cover all the key aspects of orphan drug legislation in both the US and EU and the regulatory processes designed to enable early access to innovative medicines. The programme will help you to assess the strategic considerations of when to apply for orphan designation and to which agency and look at the development of advanced therapies and using orphan drug designation with your ATMP strategy.
A case study session on how to prepare and manage an orphan drug submission will consolidate learning and ensure that you leave the event with practical skills and knowledge that can be put to use in the workplace. The course will allow you not only to learn from our expert trainer but also to share the experiences of other delegates.Benefits of attending:
This event will be particularly relevant to regulatory affairs professionals who are involved in orphan drug submissions. It will also be of interest to those working in rare diseases who would benefit from an overview of orphan drug designation.
Practical case study session on obtaining orphan drug designationOrphan drugs and ATMPs
|17 Mar 2020|
|17 Mar 2020||Rembrandt Hotel, London||GBP 699.00
+ VAT @ 20.00%
Until 14 Feb*
|23 Sep 2020|
|23 Sep 2020||Rembrandt Hotel, London||GBP 699.00
+ VAT @ 20.00%
* Note the early booking discount cannot be combined with any other offers or promotional code